Literature DB >> 6238227

Vitamin C in the treatment of acquired immune deficiency syndrome (AIDS).

R F Cathcart.   

Abstract

My previous experience with the utilization of ascorbic acid in the treatment of viral diseases led me to hypothesize that ascorbate would be of value in the treatment of AIDS (acquired immune deficiency syndrome). Preliminary clinical evidence is that massive doses of ascorbate (50-200 grams per 24 hours) can suppress the symptoms of the disease and can markedly reduce the tendency for secondary infections. In combination with usual treatments for the secondary infections, large doses of ascorbate will often produce a clinical remission which shows every evidence of being prolonged if treatment is continued. This clinical remission is achieved despite continuing laboratory evidence of helper T-cell suppression. There may be a complete or partial destruction of the helper T-cells during an initial infection that does not necessitate a continuing toxicity from some source to maintain a permanent or prolonged helper T-cell suppression. However, it is possible ascorbate may prevent that destruction if used adequately during that prodrome period. Emphasis is put upon the recognition and treatment of the frequent intestinal parasites. Food and chemical sensitivities occur frequently in the AID syndrome and may aggravate symptoms considered to be part of the AID syndrome. A topical C-paste has been found very effective in the treatment of herpes simplex and, to a lesser extent, in the treatment of some Kaposi's lesions. Increasingly, clinical research on other methods of treating AIDS is being "contaminated" by patients taking ascorbate.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6238227     DOI: 10.1016/0306-9877(84)90149-x

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  11 in total

Review 1.  Vitamins and minerals in HIV infection.

Authors:  G Coodley; D E Girard
Journal:  J Gen Intern Med       Date:  1991 Sep-Oct       Impact factor: 5.128

2.  Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy.

Authors:  A Kataoka; H Imai; S Inayoshi; T Tsuda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

3.  Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency.

Authors:  D C Rees; H Kelsey; J D Richards
Journal:  BMJ       Date:  1993-03-27

Review 4.  Vitamin C, Pain and Opioid Use Disorder.

Authors:  Erica Zelfand
Journal:  Integr Med (Encinitas)       Date:  2020-06

5.  Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells.

Authors:  S Harakeh; R J Jariwalla; L Pauling
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 6.  Micronutrients in Sepsis and COVID-19: A Narrative Review on What We Have Learned and What We Want to Know in Future Trials.

Authors:  Matteo Rossetti; Gennaro Martucci; Christina Starchl; Karin Amrein
Journal:  Medicina (Kaunas)       Date:  2021-04-26       Impact factor: 2.430

7.  Phytochemical studies and antioxidant activity of two South African medicinal plants traditionally used for the management of opportunistic fungal infections in HIV/AIDS patients.

Authors:  Wilfred Mbeng Otang; Donald Scott Grierson; Roland Ndip Ndip
Journal:  BMC Complement Altern Med       Date:  2012-04-13       Impact factor: 3.659

Review 8.  Role of vitamin C in preventing of COVID-19 infection, progression and severity.

Authors:  Umar Shahbaz; Nazira Fatima; Samra Basharat; Asma Bibi; Xiaobin Yu; Muhammad Iftikhar Hussain; Maryam Nasrullah
Journal:  AIMS Microbiol       Date:  2022-03-30

9.  Modulation of LPS-induced CD4+ T-cell activation and apoptosis by antioxidants in untreated asymptomatic HIV infected participants: an in vitro study.

Authors:  S Mburu; J L Marnewick; A Abayomi; H Ipp
Journal:  Clin Dev Immunol       Date:  2013-11-21

Review 10.  Overview of the possible role of vitamin C in management of COVID-19.

Authors:  Anis Abobaker; Aboubaker Alzwi; Alsalheen Hamed A Alraied
Journal:  Pharmacol Rep       Date:  2020-10-28       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.